Zacks Research Forecasts Qiagen’s Q4 Earnings (NYSE:QGEN)

Qiagen (NYSE:QGEN) – Equities research analysts at Zacks Research cut their Q4 2025 EPS estimates for shares of Qiagen in a report released on Wednesday, February 26th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.63 per share for the quarter, down from their previous estimate of $0.64. The consensus estimate for Qiagen’s current full-year earnings is $2.26 per share. Zacks Research also issued estimates for Qiagen’s Q1 2026 earnings at $0.51 EPS and FY2027 earnings at $2.69 EPS.

QGEN has been the subject of several other research reports. Baird R W downgraded shares of Qiagen from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 19th. Jefferies Financial Group restated a “buy” rating and set a $52.50 price target (up from $40.83) on shares of Qiagen in a research report on Tuesday, December 10th. Morgan Stanley reiterated an “equal weight” rating and issued a $46.67 price objective (down previously from $48.61) on shares of Qiagen in a report on Monday, January 6th. Robert W. Baird lowered Qiagen from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $52.00 to $42.00 in a research note on Wednesday, February 19th. Finally, UBS Group dropped their target price on Qiagen from $50.00 to $48.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Seven equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $47.71.

Qiagen Price Performance

Shares of QGEN opened at $38.38 on Friday. The firm has a 50-day simple moving average of $42.81 and a two-hundred day simple moving average of $42.94. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.61 and a quick ratio of 3.09. Qiagen has a 1-year low of $38.29 and a 1-year high of $49.30. The stock has a market cap of $8.51 billion, a PE ratio of 106.86, a P/E/G ratio of 2.39 and a beta of 0.36.

Qiagen (NYSE:QGEN) last posted its earnings results on Wednesday, February 5th. The company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.60 by $0.01. Qiagen had a return on equity of 13.92% and a net margin of 4.23%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in QGEN. Groupama Asset Managment grew its stake in shares of Qiagen by 8,074.0% during the fourth quarter. Groupama Asset Managment now owns 31,817,740 shares of the company’s stock worth $1,416,844,000 after purchasing an additional 32,216,761 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Qiagen by 9.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 25,319,332 shares of the company’s stock worth $1,127,470,000 after acquiring an additional 2,202,040 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Qiagen by 2.5% in the 4th quarter. Wellington Management Group LLP now owns 21,782,305 shares of the company’s stock valued at $970,534,000 after acquiring an additional 531,362 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Qiagen by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 8,879,089 shares of the company’s stock valued at $397,937,000 after acquiring an additional 77,119 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Qiagen during the 4th quarter worth about $181,529,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.